Jong-Hyeon Jeong

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

A parametric model for long-term follow-up data from phase III breast cancer clinical trials.

Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma.

Rank tests for clustered survival data.

Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.

Rank tests for clustered survival data when dependent subunits are randomized.

Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy.

Parametric regression on cumulative incidence function.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data.

Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity.

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.

Nonparametric inference on median residual life function.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

Statistical analysis in cancer clinical trials.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

A new generalization of Weibull distribution with application to a breast cancer data set.

Regression on quantile residual life.

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Pitfalls of using composite primary end points in the presence of competing risks.

Predictors of competing mortality in early breast cancer.

Amenorrhea from breast cancer therapy--not a matter of dose.

Empirical likelihood ratio test for median and mean residual lifetime.

Breast cancer adjuvant therapy: time to consider its time-dependent effects.

Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Population-based study of competing mortality in head and neck cancer.

Censored quantile regression for residual lifetimes.

Bayesian nonparametric inference on quantile residual life function: Application to breast cancer data.

Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Nonparametric inference on cause-specific quantile residual life.

Constrained parametric model for simultaneous inference of two cumulative incidence functions.

Median tests for censored survival data; a contingency table approach.

Reply to V. Pitini et al.

An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Stationary versus agitated storage of whole blood during acute normovolemic hemodilution.